- Home
- » Tags
- » PARP inhibitor
Top View
- PARP Traps Rescue the Pro-Inflammatory Response Of
- CHMP Assessment Report
- Opportunities for the Repurposing of PARP Inhibitors for the Therapy of Non-Oncological Diseases
- Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
- Exposure Time Versus Cytotoxicity for Anticancer Agents
- Phosphoinositide 3-Kinase Inhibitors Induce DNA Damage Through Nucleoside Depletion
- Identifying and Overcoming Mechanisms of PARP Inhibitor
- The Biochemical and Cellular Basis for Nutraceutical Strategies to Attenuate Neurodegeneration in Parkinson's Disease
- Untersuchungen Zur Expression Des Immunmodulatorischen Proteins PD-L1 Im Urothelkarzinom Der Harnblase
- Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms Keith W
- PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers Patrick G
- Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC
- Biomarker Based Therapy in Pancreatic Ductal Adenocarcinoma: an Emerging Reality?
- Targeting Autophagy Potentiates the Anti-Tumor Effect of PARP Inhibitor in Pediatric Chronic Myeloid Leukemia
- Severe Folate Deficiency Anemia Associated with the Use of a PARP
- Restrained Management of Copper Level Enhances the Antineoplastic Activity of Imatinib in Vitro and in Vivo
- CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer
- Parp Inhibitor Olaparib Is Safe and Effective in Patients with BRCA1 and BRCA2 Mutations
- Co-Encapsulation of Methylene Blue and PARP-Inhibitor Into Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Enhanced PDT of Cancer
- PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast 2 Cancer to Ionizing Radiation 3
- Combining DNA Damaging Therapeutics with Immunotherapy: More Haste, Less Speed
- The Key Role of Transient Receptor Potential Melastatin-2 Channels in Amyloid-B-Induced Neurovascular Dysfunction
- ALDH1A1 Contributes to PARP Inhibitor Resistance Via Enhancing
- Pancreatic Cancer: a Therapeutic Challenge Yet to Be Met
- Triple‑Negative Breast Cancer Therapy: Current and Future Perspectives (Review)
- Lynparza 100 Mg Film-Coated Tablets
- Brain Sciences
- Polymerization
- Phase I Clinical Trials VOLUME 14, NO
- Vol. 33 | 4/2017
- The Suppression of DNA Repair Induced by PARP-1 Inhibitors Rucaparib and Olaparib in Combination with the Radiopharmaceutical 13
- Study Protocol 3000-PN162-01-001 Amendment 2
- PARP Inhibitors: the Race Is On
- Role of Free Radicals in PARP Inhibition of Cervical Carcinogenesis: Parylation of Hela Cells, and Inhibition of Hparp-1 Enzyme Clifford Fong
- Poly Adp Ribose Polymerase and the Therapeutic Effects of Its Inhibitors
- Calbiochem Inhibitor Sourcebook
- Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
- The Role of Poly(ADP-Ribose) Polymerase Inhibitors in The
- (12) Patent Application Publication (10) Pub. No.: US 2012/0076770 A1 Espina Et Al
- Mechanisms of Multidrug Resistance in Cancer Chemotherapy
- A Phase I Study of the PARP Inhibitor Niraparib in Combination with Bevacizumab in Platinum-Sensitive Epithelial Ovarian Cancer
- PARP Inhibition Causes Premature Loss of Cohesion in Cancer Cells
- The Role of PARP in DNA Repair and Its Therapeutic Exploitation
- NEW DRUG FAX SHEET Volume 22 (Issue 4) April 17, 2017
- Recent Advances of Wee1 Inhibitors and Statins in Gynecologic Cancers with P53 Mutations
- Lynparza (Olaparib) Tablets for Oral Use Contain 100 Mg Or 150 Mg of Olaparib
- Analysis of PARP Inhibitor Toxicity by Multidimensional fluorescence Microscopy Reveals Mechanisms of Sensitivity and Resistance
- 208447Orig1s000
- LYNPARZA Capsules Product Information
- LYNPARZA (Olaparib)
- Prevention of the Degeneration of Human Dopaminergic Neurons in an Astrocyte Co-Culture System Allowing Endogenous Drug Metaboli
- PARP Inhibitor
- Mrna Median Score Name Description 1 99.7 Etoposide
- A Src/Abl Kinase Inhibitor, Bosutinib, Downregulates and Inhibits PARP
- Poly(ADP-Ribose)Polymerase Inhibition Counteracts Cataract Formation and Early Retinal Changes in Streptozotocin-Diabetic Rats
- The Off-Target Kinase Landscape of Clinical PARP Inhibitors
- Targeted PARP Inhibition Combined with FGFR1 Blockade Is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer
- Challenges and Opportunities for Childhood Cancer Drug Development
- Current State and Future Perspectives in Breast Cancer
- Development of PARP and Immune-Checkpoint Inhibitor Combinations Ross a Stewart1, Patrick G Pilie 2, and Timothy a Yap3